ANNOUNCEMENT 07 Jan 2019

In January 2019, the European Investment Bank (EIB) signed a loan agreement with Novozymes A/S to support its development of certain biological solutions, microorganisms and industrial enzymes. 

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

The European Investment Bank, Financed Projects, NOVOZYMES BIOTECHNOLOGY INNOVATION II: http://www.eib.org/en/projects/loan/loan/20180291
The European Investment Bank, Project summary, NOVOZYMES BIOTECHNOLOGY INNOVATION II: http://www.eib.org/en/projects/pipelines/pipeline/20180291
Novozymes A/S: https://www.novozymes.com/en/about-us

Inception date: 07 Jan 2019 | Removal date: open ended

State loan

The loan agreement between the European Investment Bank (EIB) and Novozymes A/S was signed on 7 January 2019 and has a total value of EUR 100 million (approx. USD 114.7 million).

The loan will support the company's RDI project concerning the development of certain biological solutions, microorganisms and industrial enzymes. More specifically, the EIB stated: "The RDI activities will focus on the development of products and solutions that enhance product quality and process/energy efficiency in industries such as detergents, food and beverages, bioenergy, agriculture and feed and technical industries."

Novozymes A/S has its headquarters in Denmark and is a producer of microorganisms and industrial enzymes. The company holds a 48% market share in industrial enzymes and sells its products to 130 countries around the world.

A state act in the GTA database is assessed solely in terms of the extent to which its implementation affects foreign commercial interests. On this metric, the investment support granted here is discriminatory.

AFFECTED SECTORS

 

AFFECTED PRODUCTS